A Phase I Pharmacodynamic Study of Copanlisib (BAY 80-6946) as Monotherapy in Patients With Non-Hodgkin's Lymphoma and Solid Tumors

Trial Profile

A Phase I Pharmacodynamic Study of Copanlisib (BAY 80-6946) as Monotherapy in Patients With Non-Hodgkin's Lymphoma and Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2018

At a glance

  • Drugs Copanlisib (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Pharmacodynamics
  • Sponsors Bayer
  • Most Recent Events

    • 24 Mar 2018 Results exploring the relationship between copanlisib pharmacokinetic (PK) and pharmacodynamic (PD) effects in a phase I study in subjects with NHL and solid tumors presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 12 Dec 2017 Results assessing dose dependent pharmacodynamic effects of copanlisib relative to plasma exposure presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 07 Dec 2017 According to a Bayer media release, data from the study will be presented at the 59th Annual Meeting of the American Society of Hematology (ASH).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top